LONDON, UNITED KINGDOM--(MARKET WIRE)--Feb 19, 2008 -- NextGen Bioscience, Inc. ("NextGen") (OTC BB:NXGB.OB - News), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced that it is in collaboration negotiations with Warburg Glycomed, a biopharmaceutical company that has developed a new class of drugs which has shown potent anti-cancer properties in animal models.
The company, Warburg Glycomed GmbH ("Warburg Glycomed") has a patent-protected compound that is able to reprogram cancer cells by modulating their aerobic glucose metabolism, which affects their ability to grow. Warburg Glycomed has expressed keen interest in collaborating with NextGen in a recently signed Letter of Intent, and is confident that a mutually beneficial deal can be arranged.
Konstantinos Kardiasmenos, CEO of NextGen, stated, "These collaboration discussions with Warburg Glycomed represent progress on fulfilling our business goal to form international collaboration agreements with specialty research organisations. An alliance with Warburg Glycomed would strengthen both companies' position to capture the phenomenal global market for therapeutic cancer agents, which is now reaching a volume of approximately $30 Billion."
About Warburg Glycomed GmbH
Warburg Glycomed is a biopharmaceutical company focused in the development, production and marketing of drugs which inhibit the proliferation of cells with typical tumor cell like metabolism. Warburg Glycomed has already shown in previous in vitro and in vivo studies that the reversion of the so-called Warburg effect can be best achieved with butanoic acid derivatives while showing the least side effects. Warburg Glycomed has claimed this compound class and has successfully shown inhibition of tumor growth as well as and total tumor regressions in a rat model.
The Warburg Glycomed vision is to be the scientific and therapeutic leader in the field of treatment of proliferating cells with a focus on the cancer cell metabolism. As a company it strives to provide curing agents for cancer and by that means improve the quality of treatment for cancer patients.
About NextGen Bioscience Inc.
NextGen is positioning itself as the world's leading bioscience company in the development and commercial licensure of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.
At present, NextGen is rapidly building its portfolio of proprietary biotechnology. NextGen's target market --cancer treatments-- is the largest disease market, exploding at a 20% growth rate each year. NextGen's treatment niche is based on recent discoveries that indicate that many tumors are derived from a single cancer-initiating cell population which has stem cell properties (a cancer stem cell). NextGen has chosen to concentrate on identification of certain cell-specific characteristics, making it possible to identify precursor cells of tumors, and then conduct a more extensive 'fingerprinting' profile that will enable the development of cell-specific anti-cancer treatments. This will result in a 'tailor made' cancer treatment strategy that is superior to existing therapies in its ability to eradicate malignant cells whilst leaving healthy tissue intact.
Statements about NextGen's future expectations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. NextGen's actual results could differ materially from expected results. NextGen undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.
For more information about NextGen Bioscience Inc., or to schedule an interview with Mr. Kardiasmenos, please contact Graham May at +44 20 7247 8186 or email@example.com.
NextGen Bioscience, Inc.
+44 (0) 20 7247 8186
+44 (0) 20 7377 9454 (FAX)
Source: NextGen Bioscience, Inc.